Personalized immunotherapy to fight HIV/AIDSAugust 18, 2008For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City. "Our approach is unique in the world: no one else has yet developed customized immunotherapy using the virus from individual patients," said Dr. Routy. "This experimental technique remains long and costly for the moment, but we're hoping it will hold the promise of a completely innovative and widely available treatment in the future." This immunotherapy is based on the properties of dendritic cells, whose role is to present specific proteins from infectious organisms at their surface, thereby alerting the rest of the immune system. In collaboration with Argos Therapeutics, the researchers designed a study in which the dendritic cells of nine study patients were multiplied in vitro and then treated with the RNA (ribonucleic acid) from the virus that had infected each patient. A virus sample was taken before the administration of any antiretroviral treatment. The surfaces of these manipulated dendritic cells present an increased number of HIV proteins, which allows them to stimulate the cytotoxic response of a certain type of immune cell called CD8+ lymphocytes. After receiving multiple subcutaneous injections of these dendritic cells, eight of the nine patients involved experienced a significant increase in CD8+ lymphocyte activity. "At this stage, we have shown that the technique doesn't cause side effects or an undesirable auto-immune response," said Dr. Routy. "Health Canada has approved a multicentre clinical trial across the country that will let us further assess the technique's effectiveness at controlling HIV reproduction. We're hoping that the FDA in the United States will also give us the go-ahead soon so that our pharmaceutical partner, Argos Therapeutics, can begin testing in the United States." While more research needs to be done, this new target may lead to an innovative therapeutic approach to fight the AIDS pandemic. McGill University Health Centre |
|||||||||||||||||||||
| Related Immunotherapy Current Events and Immunotherapy News Articles Immune system activated in schizophrenia Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system. Hundreds of genes distinguish patients likely to survive advanced melanoma Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Immunotherapy demonstrates long-term success in treating lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). Alzheimer's lesions found in the retina The eyes may be the windows to the soul, but new research indicates they also may mirror a brain ravaged by Alzheimer's disease. Elderly immune system needs a boost Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease. Oleocanthal may help prevent, treat Alzheimer's Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells. University Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. Mounting a multi-layered attack on fungal infections Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened. Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna. Researchers testing virus-gene therapy combination against melanoma Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease. More Immunotherapy Current Events and Immunotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||